CYP2C19 and cardiovascular disorder: Antiplatelet therapy with clopidogrel is a standard-of-care for the prevention and treatment of atherothrombotic cardiovascular disease and potential for drug–drug interactions, due to CYP2C19 inhibition, is an important clinical challenge in these groups of patients and often requiring careful monitoring.